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Abstract: The objective was to investigate the usefulness of the “liquid biopsy” of aqueous humor
(AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for
treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first
anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three
groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11),
and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids
but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines,
chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found
higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders.
In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers
than rapid responders, but did not reach statistical significance. Finally, those patients who responded
to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than
patients with rapid response (p = 0.01). In conclusion, “liquid biopsy” of AH could be useful to
determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in
nature. This approach would allow physicians to select a more rational and cost-effective treatment.
Further studies to validate these preliminary results are warranted.
Keywords: diabetic macular edema; anti-VEGF agents; aqueous humor; biomarkers; VEGF;
inflammation; personalized medicine
1. Introduction
Diabetic retinopathy (DR) prevalence in the diabetic population is around one-third, and one-tenth
has vision-threatening states such as diabetic macular edema (DME) or proliferative diabetic retinopathy
(PDR) [1]. While PDR is the most common sight-threatening complication in type one diabetes, DME is
the primary cause of poor visual acuity in type two diabetes [2]. Because of the high prevalence of
type two diabetes, DME is the main cause of visual impairment in diabetic patients. In addition, DME
is almost invariably present when PDR is detected in type two diabetes [3].
The hallmark feature of DME is the alteration of the blood-retinal barrier (BRB). Inflammation
plays a crucial role in DME with the involvement of several chemokines and cytokines, including
J. Clin. Med. 2019, 8, 1841; doi:10.3390/jcm8111841 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 1841 2 of 9
vascular endothelial growth factor (VEGF) [4–6]. Intravitreal anti-VEGF agents have emerged as new
treatments for the more advanced stages of DR [7–9]. In recent years, the results of major randomized
controlled clinical trials investigating the use of anti-VEGF therapy for DME have been reported.
These trials provide robust evidence that intraocular administration of anti-VEGF agents is better than
laser therapy both in preserving and in improving vision for patients with DME. However, around 50%
of DME patients did not adequately respond to anti-VEGF therapy [5]. These findings strongly suggest
that other molecules and mechanisms may operate independently or in conjunction with VEGF in
the pathogenesis of this disease, with proinflammatory cytokines being one of the most significant
players [5]. In the classical study of Aiello et al. [10], more than half of the patients with PDR did not
show increased VEGF levels in the vitreous fluid. Therefore, it is not surprising that approximately
half of patients with DME do not show adequate response to anti-VEGF treatment. In this subgroup of
non-responders other growth factors and/or proinflammatory cytokines unrelated to VEGF probably
play a more relevant pathogenic role.
Proteins secreted by the retina enter the vitreous and, therefore, concentration levels of particular
proteins in the vitreous could be used as markers of the function or dysfunction of the retina [11].
Furthermore, most of the proteins secreted into the vitreous diffuse into the aqueous humor (AH)
which fills the anterior chamber. Since the concentration of a protein in AH may reflect its level in
the vitreous and the retina [12,13], the analysis of the AH obtained at the time of the first intravitreal
injection could be useful for examining whether the predominant pathogenic event is inflammation
or the increase of VEGF or other growth factors. This approach would be useful for selecting a more
rational and probably a most cost-effective treatment for DME [14]. However, data available on liquid
biopsy of AH as a tool for predicting the response to anti-VEGF treatment are scarce and sometimes
conflictive [15,16].
The main aim of the present study was to investigate the usefulness of a panel of cytokines
and growth factors obtained from AH of patients with DME as predictors of the clinical response to
intravitreal injections of anti-VEGF agents. In addition, the correlation between vitreous and aqueous
levels of VEGF was examined.
2. Experimental Section
2.1. Patients
This was a retrospective study comprising a total of 31 consecutive type two diabetic patients who
received anti-VEGF intravitreal injections (either ranibizumab (25% of patients) or aflibercept (75%)) for
the treatment of DME between January 2017 and June 2018 in a tertiary hospital. A subset of type two
diabetic subjects (n = 7) with a good response to intravitreal corticosteroids (dexamethasone implant)
but with incomplete response to anti-VEGF therapy was also analyzed. In all cases, the sample of
AH was obtained at the first intravitreal injection of anti-VEGF. All enrolled patients gave informed
consent for the procedure and for entering the study.
Apart from ophthalmologic data (i.e., best-corrected visual acuity (BCVA), funduscopic
examinations and spectral-domain optical coherence tomography (SD-OCT) assessments), the clinical
variables obtained in all patients included in the study were as follows: age, gender, duration of
diabetes, presence and degree of DR, metabolic control (HbA1c values), and any other systemic or
ocular treatment received during the follow-up. The duration of the study was 18 months.
A volume of≈ 0.1 mL of AH was obtained using a limbal approach with a 30 gauge needle. In 7 out
of 38 patients, 1–2 mL of vitreous fluid was also obtained during 23 gauge pars plana vitrectomy [17].
The samples were immediately transferred to sterile plastic tubes, frozen, and stored at −80◦ until
the analyses.
The study was conducted according to the Declaration of Helsinki and was approved by the
Ethics Committee of Vall d’Hebron University Hospital.
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2.2. Definition of Response to Treatment
The response to corticosteroid treatment with dexamethasone intravitreal implant can be generally
established after the first injection and in the present study it was defined as a ≥50% reduction in
central retinal thickness (CRT) at 6–8 weeks [18]. Conversely, evidence shows that the response to
anti-VEGF therapy could not appear after the first injection [19] and, therefore, it was decided to wait
to after a period of loading doses (3–5 monthly intravitreal administrations) to classify the response
into three categories:
(1) Rapid response: reduction >50% in CRT at three months (one month after the third injection);
(2) Slow response: reduction between 10–50% in CRT at three months, but >50% at five months
(one month after the fifth injection);
(3) No response: <20% reduction in CRT at both three and five months [20].
It should be noted that reductions in CRT are not referred from baseline, but reduction of >50% of
excess CRT (defined as CRT difference from baseline and 250 µm).
2.3. Aqueous and Vitreous Humor Measurements
Analyses were performed with MILLIPLEX® Multiplex Assays (Merck-Millipore, Darmstadt,
Germany) using a Luminex-MAGPIX® platform (Luminex Corporation, Austin, TX, USA). Levels from
17 factors were measured by using the following two panels: HCYTOMAG-60K-10 (EGF, IL-1β, IL-6,
IL-8, IL-10, IL-12p70, PDGF-AA, PDGF-AB/BB, TNF-α, VEGF-A) and SPR1284 (PlGF, angiopoetin-2,
HGF, sTNFR-I, sTNFR-II, MMP-9).
The coefficient of intra-assay variation and lower detection limits are displayed in Table 1.
Table 1. Coefficient of intra-assay variation and lower detection limits.
CV Intra-Assay Low Limit of Detection (pg/mL)
VEGF 0.57% 2.76
PlGF 0.19% 0.05
HGF 0.76% 1.50
EGF 13.85% 2.49
Angiopoietin 2 0.56% 2.41
PDGF-AA 0.65% 0.88
PDGF-AB/BB 0.94% 1.30
MMP-9 0.17% 1.10
IL-1β 1.16% 0.24
IL-6 1.15% 0.78
IL-8 0.51% 1.20
IL-10 0.71% 1.75
IL-12p70 0.59% 1.69
TNF-α 1.02% 1.41
TNFR1 0.36% 4.59
TNFR2 0.55% 9.00
CV: Coefficient of variation; VEGF: Vascular endothelial growth factor; PlGF: placental growth factor;
HGF: hepatocyte growth factor; EGF: epidermal growth factor; PDGF: platelet derived growth factor; MMP: matrix
metalloproteinase; IL: interleukin; TNF: tumor necrosis factor; TNFR: tumor necrosis factor receptor.
2.4. Statistical Analyses
Comparisons between groups were made using the Student’s t test for continuous variables and
the χ2 test for categorical variables. The relationship between the continuous variables was examined
by Spearman’s rank correlations. All p values were based on a two-sided test of statistical significance.
Significance was accepted at the level of p < 0.05. Statistical analyses were performed using the SSPS
statistical package (SPSS, Chicago, IL, USA).
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3. Results
The baseline characteristics of diabetic patients treated with anti-VEGF agents included in the
study are specified in Table 2. The three groups were balanced regarding metabolic control (HbA1c),
central retinal thickness and macular volume SD-OCT parameters.
Table 2. Characteristics of diabetic patients treated with anti-VEGF agents.
Rapid-Response to
anti-VEGF (n = 11)
Slow-Response to
anti-VEGF (n = 11)
Non-Response to
anti-VEGF (n = 9) p-Value
Gender (M/F) 6/5 6/5 7/2 n.s.
Age (years) 67.5 ± 9.7 71 ± 6.9 68.1 ± 11.6 n.s.
Diabetes duration
(years) 12.7 ± 2.6 12.9 ± 2.6 11.6 ± 2.9 n.s.
HbA1c (%) 7.75 ± 1.34 7.54 ± 1.11 7.84 ± 1.3 n.s.
Insulin treatment (%) 70 81.8 33.3 n.s.
Phakic status (%) n.s.
No cataract 4 2 5
Cataract 0 1 0
Previous cataract
surgery 6 8 4
Glaucoma (%) 10 27.3 33.3 n.s.
NPDR (%) / PDR (%) 91 / 9 82/18 89/11 n.s.
Central Retinal
Thickness (µm) 443 ± 91 542 ± 179 449 ± 67 n.s.
Macular volume
(mm3) 9.67 ± 1.83 11.55 ± 4.16 9.62 ± 1.37 n.s.
Mean BCVA
(ETDRS letters) 65 (20/50) 67.2 (20/50) 62.5 (20/63) n.s.
VEGF: Vascular Endothelial Growth Factor; M/F: Male, female; NPDR: non-proliferative diabetic retinopathy;
PDR: proliferative diabetic retinopathy. BCVA: best corrected visual acuity. ETDRS: Early Treatment Diabetic
Retinopathy Study.
Regarding diabetic retinopathy (DR) progression, none of the patients experienced worsening
and 35% improved at least two steps in the DR severity scale compared to baseline. The improvement
of DR was independent to the response of the macular edema.
The results of all the factors analyzed according to the response are summarized in Table 3.
We found significantly higher levels (pg/mL) of VEGF in AH in rapid responders vs. non-responders
(62.2 pg/mL (10–160) vs. 2.7 pg/mL (2.7–55); p = 0.03). In addition, a tendency (p = 0.08) towards
showing higher AH VEGF levels in rapid vs. slow responders was observed. Conversely, in those
patients who responded to corticosteroids but not to anti-VEGF agents, we found significantly lower
levels of VEGF in comparison with rapid responders (Figure 1). Notably, we found a strong correlation
between VEGF concentrations in vitreous and AH (r = 0.81; p < 0.05) (Figure 2).
Table 3. Concentration of growth factors and cytokines in aqueous humor (AH) according to anti-VEGF
treatment response.
Rapid-Response to
anti-VEGF (n = 11)
Delayed-Response
to anti-VEGF (n = 11)
Non-Response to
anti-VEGF (n = 9) p-Value
Group 1 2 3
VEGF (pg/mL) 62.2 (10–160) 10.1 (2.7–26.8) 2.7 (2.7–55) 0.08 *
0.03 **
PIGF (pg/mL) 266 (3.8–266) 266 (8.9–266) 266 (2.6–266) 0.84 *
0.99 **
HGF (pg/mL) 343 (35.19–433) 482 (198–2036) 258 (177–759) 0.15 *
0.94 **
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Table 3. Cont.
Rapid-Response to
anti-VEGF (n = 11)
Delayed-Response
to anti-VEGF (n = 11)
Non-Response to
anti-VEGF (n = 9) p-Value
Angiopoietin-2
(pg/mL) 5.6 (4.5–20.7) 15.5 (5.6–30.62) 6.8 (2–21.9)
0.13 *
0.88 **
PDGF-AA (pg/mL) 18.9 (6.8–18.9) 27.2 (22–27.3) 13 (11.2–17.5) 0.74 *
0.37 **
MMP-9 (pg/mL) 74.3 (28.4–174) 237 (93.4–282) 73 (2–182) 0.07 *
0.41 **
IL-6 (pg/mL) 4 (0.7–17) 6.7 (3–13.6) 1.52 (0.7–7.7) 0.51 *
0.71 **
IL-8 (pg/mL) 3.2 (1.6–10.6) 11.5 (4.1–25.8) 4.9 (2.3–12.4) 0.07*
0.60 **
TNFR1 (pg/mL) 122 (32.5–168) 171 (91.4–307) 114 (46.5–219) 0.10 *
0.90 **
TNFR2 (pg/mL) 215 (85.3–372) 340 (210–755) 234 (124–352) 0.07 *
0.76 **
Data are median (CI 25%–75%). *: p-value between group 1 and group 2, **: p-value between group 1 and group 3.
VEGF: Vascular endothelial growth factor; PlGF: placental growth factor; HGF: hepatocyte growth factor; PDGF:
platelet derived growth factor; MMP: matrix metalloproteinase; IL: interleukin; TNF: tumor necrosis factor; TNFR:
tumor necrosis factor receptor.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 6 of 10 
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Figure 1. VEGF levels in aqueous humor according to response. Individual data points, median
(horizontal bar symbols) and p values are shown.
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Figure 2. Correlation between aqueous and vitreous levels of VEGF.
Levels of IL-1β, IL-10, IL-12, EGF, TNF-α, and PDGF-AB/BB were found to be undetectable in
most samples. Therefore, only PlGF, HGF, angiopoietin-2, PDF-AA, MMP-9, IL-6, IL-8, TNFR1 and
TNFR2 were analyzed. Slow responders to anti-VEGF therapy showed higher levels of inflammatory
markers (IL-6, IL-8, TNFR1, TNFR2 and MMP-9) than rapid responders, but these differences did not
reach statistical significance (Table 3).
4. Discussion
In the present study, we found significantly higher baseline levels of VEGF in the AH of the
rapid responders group, in comparison with non-responders to anti-VEGF treatment. In addition,
those patients who responded to corticosteroids but not to anti-VEGF agents showed significantly
lower levels of VEGF than patients with rapid response. These results point to AH ‘liquid biopsy’
as a potentially useful tool for decision making regarding DME treatment selection based upon
pathophysiological reasons.
Several studies have investigated the predictive value of AH analysis in the DME treatment
response. However, the results of those studies show substantial heterogeneity and variability. On the
one hand, Shimura et al. [15] showed that good responders to ranibizumab presented significantly
increased baseline AH VEGF concentrations. In contrast, Hillier et al. [16] reported that elevated
baseline AH VEGF levels were associated with a less favorable SD-OCT macular volume response
to ranibizumab. Those conflicting results could be explained by differences in the characteristics of
patients included and the definition of response. For instance, in the study of Hillier et al. [16], both type
one and type two diabetic patients were included and the mean levels of HbA1C were higher than 8%,
whereas in Shimura’s paper [15], as well as in the present study, only type two diabetic patients were
included and glycemic control was better (a mean of HbA1c lower than 8%). Unfortunately, the impact
of blood glucose control in the efficacy of anti-VEGF therapies for DME was not evaluated in the
pivotal clinical trials assessing the effectiveness of anti-VEGF agents for the treatment of DME [21–24].
Nonetheless, there is evidence that high levels of HbA1c at baseline are associated with poor response
to intravitreal anti-VEGF therapy [25–27]. This is an important point that merits a specific study in
which not only baseline HbA1c should be taken into account, but also glycemic variability and the
metabolic control after intravitreal anti-VEGF injections.
Additionally, in the study of Shimura et al. [15] as well as in the present study, mean levels of
VEGF in AH were under 200 pg/mL, whereas in the study of Hillier et al. [16] mean VEGF levels were
higher than 750 pg/mL. This difference could be attributed to the inclusion of patients with retinal
J. Clin. Med. 2019, 8, 1841 7 of 9
ischemia, a well-recognized factor that upregulates VEGF production, thus limiting the effectiveness
of anti-VEGF treatment. The methodological differences could also contribute to the discrepancy of
the results. In this regard, it is worth mentioning that we found a strong correlation between the
concentration of VEGF in vitreous and aqueous samples obtained simultaneously, thus demonstrating
that our samples of AH indeed reflected the events that occurred at retinal level.
The current body of evidence shows that in patients with type two diabetes, there is a low grade of
systemic inflammation, and both adipose tissue and macrophages are thought to be the main sources
of systemic proinflammatory cytokine production [28]. Plasma diffusion favored by the breakdown of
the BRB in patients with DME could increase the levels of these cytokines in ocular fluids. However,
local synthesis is the most important source of proinflammatory cytokines/chemokines involved in
DME [11]. Indeed, we have found that levels of VEGF were significantly higher in vitreous fluid than
in serum of patients with PDR but not in non-diabetic subjects [29]. We also found that other cytokines
such as IL-8 and MCP-1 were strikingly higher in vitreous fluid than in serum of patients with PDR [30].
Notably, the vitreous levels of both IL-8 and MCP-1 were similar to those detected in pleural effusions
of patients with pneumonia or tuberculosis. Other authors have reported a significant alteration of
inflammatory cytokines in AH and their relationship with the disease severity not only in DME [31]
but also in DR [32].
Although AH does not reflect so closely the events that are taking place in the retina as vitreous
fluid, it is more easily obtained and therefore “liquid biopsy” of AH could be incorporated into
current clinical practice. In the present study we have found that slow responders to anti-VEGF
exhibited higher levels of inflammatory biomarkers (IL-6, IL-8, TNFR1, TNFR2 and MMP-9) than rapid
responders, thus suggesting that inflammation is not adequately controlled by anti-VEGF agents. In
this regard, it has been reported that IL-8 concentration in AH was associated with lower responsiveness
to intravitreal bevacizumab [33]. On the other hand, a post-hoc analysis of the READ3 study, in
which DME patients were randomized to receive 0.5 or 2.0 mg ranibizumab and AH samples were
collected in a prospective manner, has revealed that those patients who presented elevated AH levels
of IL-6 at baseline ended up with worse visual outcomes when compared to those with initial low
AH IL-6 levels. These data suggest that aqueous IL-6 concentration may have prognostic therapeutic
implications, potentially representing a candidate biomarker for a less favorable response to anti-VEGF
therapy [34–36].
5. Conclusions
In conclusion, the use of AH obtained during the first intravitreal injection (“liquid biopsy”) in
treatment-naïve DME patients could be useful for determining whether the predominant pathogenic
event is the increase of VEGF or other factors. This approach would allow to implement a personalized
medicine strategy in terms of selecting a more rational and probably a more cost-effective treatment.
Further studies to validate these preliminary results are warranted.
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